161 related articles for article (PubMed ID: 36125981)
1. Identification of novel mycocompounds as inhibitors of PI3K/AKT/mTOR pathway against RCC.
Yadav RP; Chatterjee S; Chatterjee A; Pal DK; Ghosh S; Acharya K; Das M
J Recept Signal Transduct Res; 2022 Dec; 42(6):599-607. PubMed ID: 36125981
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of gypenosides of Gynostemma pentaphyllum inducing apoptosis of renal cell carcinoma by PI3K/AKT/mTOR pathway.
Liu H; Li X; Duan Y; Xie JB; Piao XL
J Ethnopharmacol; 2021 May; 271():113907. PubMed ID: 33556477
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
4. Novel targeting of phosphatidylinositol 3-kinase and mammalian target of rapamycin in renal cell carcinoma.
Cho D
Cancer J; 2013; 19(4):311-5. PubMed ID: 23867512
[TBL] [Abstract][Full Text] [Related]
5. PI3K-Akt-mTOR inhibition by GNE-477 inhibits renal cell carcinoma cell growth
Ye X; Ruan JW; Huang H; Huang WP; Zhang Y; Zhang F
Aging (Albany NY); 2020 May; 12(10):9489-9499. PubMed ID: 32421688
[TBL] [Abstract][Full Text] [Related]
6. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.
Elfiky AA; Aziz SA; Conrad PJ; Siddiqui S; Hackl W; Maira M; Robert CL; Kluger HM
J Transl Med; 2011 Aug; 9():133. PubMed ID: 21834980
[TBL] [Abstract][Full Text] [Related]
7. [Total polyphenols of Cydonia oblonga inhibited proliferation and migration of renal cancer cells by PI3K/Akt/mTOR pathway].
Abudurousuli K; Han MY; Hailati S; Maihemuti N; Talihati Z; Nueraihemaiti N; Dilimulati D; Baishan A; Aikebaier A; Zhou WT
Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):1052-1063. PubMed ID: 38621912
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic value of SC66 in human renal cell carcinoma cells.
Xu M; Wang Y; Zhou LN; Xu LJ; Jin ZC; Yang DR; Chen MB; Zhu J
Cell Death Dis; 2020 May; 11(5):353. PubMed ID: 32393791
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
10. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel natural inhibitors targeting AKT Serine/Threonine Kinase 1 (AKT1) by computational study.
Zhong S; Zhang Z; Guo Z; Yang W; Dou G; Lv X; Wang X; Ge J; Wu B; Pan X; Wang H; Mou Y
Bioengineered; 2022 May; 13(5):12003-12020. PubMed ID: 35603567
[TBL] [Abstract][Full Text] [Related]
12. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
[TBL] [Abstract][Full Text] [Related]
13. Turning down PI3K/AKT/mTOR signalling pathway by natural products: an in silico multi-target approach.
Abd Emoniem N; Mukhtar RM; Ghaboosh H; Elshamly EM; Mohamed MA; Elsaman T; Alzain AA
SAR QSAR Environ Res; 2023 Feb; 34(2):163-182. PubMed ID: 36853097
[TBL] [Abstract][Full Text] [Related]
14. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy.
Tewari D; Patni P; Bishayee A; Sah AN; Bishayee A
Semin Cancer Biol; 2022 May; 80():1-17. PubMed ID: 31866476
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products.
Iksen ; Pothongsrisit S; Pongrakhananon V
Molecules; 2021 Jul; 26(13):. PubMed ID: 34279440
[TBL] [Abstract][Full Text] [Related]
16. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma.
Kim J; Jonasch E; Alexander A; Short JD; Cai S; Wen S; Tsavachidou D; Tamboli P; Czerniak BA; Do KA; Wu KJ; Marlow LA; Wood CG; Copland JA; Walker CL
Clin Cancer Res; 2009 Jan; 15(1):81-90. PubMed ID: 19118035
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy.
Narayanankutty A
Curr Top Med Chem; 2021; 21(20):1816-1831. PubMed ID: 34279200
[TBL] [Abstract][Full Text] [Related]
18. The pro-apoptosis effect of sinomenine in renal carcinoma via inducing autophagy through inactivating PI3K/AKT/mTOR pathway.
Deng F; Ma YX; Liang L; Zhang P; Feng J
Biomed Pharmacother; 2018 Jan; 97():1269-1274. PubMed ID: 29145153
[TBL] [Abstract][Full Text] [Related]
19. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
20. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
